|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >> |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page 1 of 222 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The shares of thinly traded BioLineRx (NASDAQ:BLRX) soared as high as $5.86 
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 6, 2012.
Corcept Therapeutics (NASDAQ:CORT) is a drug discovery company focused on the development of treatments for metabolic and psychiatric disorders. Their flagship product, which has been renamed from CORLUX to the active name Korlym, is undergoing FDA review as a treatment for Cushing’s Syndrone and is also being developed (in phase III trials) for the treatment of psychotic depression.
Medgenics (NASDAQ: MDGN) has what I believe to be the most disruptive biotechnology of the last 20 years. This company is poised to own the 90 billion plus protein therapy market. We are talking about an enormous indication. Nomura (the big investment bank) Calls this one of the top 10 biotech companies to watch over the next 5 years.
During the past few sessions, we've been watching shares of OncoSec Medical Inc. (OTCBB: ONCS) rising on heavy trading so we reached out to Punit Dhillon, President and CEO for an interview to find out why investors are starting to take positions in the company after a slow but steady sell-off in the market.
Shares of PROLOR Biotech, Inc. (AMEX:PBTH) have been on the move since we told readers about the company in January and jumped another 2.81% on Tuesday.
about 3 hours ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 3 hours ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 8 hours ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 12 hours ago
$CVM up 17% and technically looks like it may head higher.
about 18 hours ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
about 18 hours ago
Catalysts on tap for Corcept: Corcept Therapeutics (NASDAQ:CORT) is a drug discovery company focused on the deve... http://t.co/jd3C1ddH
about 19 hours ago
Commented on: "Will Celsion's Upcoming Catalysts Help The Price Break-Out Stick?" http://t.co/dJ0reUFR $BSX $PHG $MDSO $CLSN
about 19 hours ago
Monday morning watch -- European Leaders Maintain Pressure on Greece to Complete Terms for Bailout - http://t.co/0wipY6QB via @BloombergNews
Free Phone Trade Alerts
